These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6441581)

  • 1. Bioavailability of orally administered mesna.
    Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
    Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B; Cerny T; Brunner KW; Küpfer A
    Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA; Mant TG; Rogers HJ
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
    Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fate of [14C]-mesna in the rat.
    Shaw IC; Graham MI; Jones MS
    Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C; Küpfer A; Schefer H; Cerny T
    Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and mesna.
    Schoenike SE; Dana WJ
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner.
    Ypsilantis P; Tentes I; Assimakopoulos SF; Kortsaris A; Scopa CD; Simopoulos C
    J Surg Res; 2004 Sep; 121(1):84-91. PubMed ID: 15313380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR; Schmähl D
    Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K; Ohno Y
    Cancer Res; 1984 Sep; 44(9):3797-800. PubMed ID: 6430554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bioavailability of mesna tablets.
    Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
    Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.